Currently, calcitonin gene-related peptide (CGRP) receptor antagonists such as atogepant, ubrogepant, and rimegepant are commonly used in combination with eptinezumab, a humanized anti-CGRP monoclonal antibody, for the treatment of migraines. Here, S100A12 is linked to migraine disorder.